Neurosoft Bioelectronics SA - Soft Brain-Computer Interface Pioneer

Company Overview (Updated April 2026)

Neurosoft Bioelectronics SA is a clinical-stage neural technology company headquartered in Geneva, Switzerland. Founded in 2020 as a spin-off from the École polytechnique fédérale de LaUSAnne (EPFL), the company specializes in developing ultra-soft, flexible neural implants and brain-computer interfaces (BCIs). The company utilizes advanced soft materials engineering and artificial intelligence to restore function in patients with neurological disorders.

Mission: To develop safe, scalable brain-computer interfaces by engineering ultra-soft minimally invasive implants that generate massive, high-fidelity neural datasets, used to train advanced AI models for precise brain decoding and breakthrough therapeutic applications for conditions such as tinnitus and epilepsy.

Corporate History and Development (2020-2026)

Founding and Early Funding (2020-2024)

- 2020: Founded as an EPFL spin-off in Geneva, Switzerland by Dr. Nicolas Vachicouras (CEO & Co-founder), Ludovic Serex, and team

- January 2021: Raised CHF 150,000 from Venture Kick

- December 2021: Raised CHF 100,000 from FONGIT (Fondation Genevoise pour l'Innovation Technologique)

- May 2023: Secured CHF 2.5 million from Innosuisse (Swiss Innovation Agency)

- February 2024: Funding from Kickfund

Human Clinical Trials (2025)

- February 2025: Successfully tested high-channel-count interface in human patients during epilepsy surgery at University Medical Center Utrecht (UMC Utrecht), Netherlands

- Study Status: 12-patient study at UMC Utrecht underway to validate technology for broader clinical use, funded by the European Research Council (ERC)

- Clinical Data: Groundbreaking technology has already been used in a dozen human patients

Science Corporation Partnership (February 2026)

- Partnership Type: Multiyear agreement to access Science's BCI Ecosystem

- Benefits: Access to complete suite of clinical-grade neural recording tools, electronics, and application development tooling

- Cost Efficiency: Reduces development cost from $75-100 million to under $5 million for first-in-human trials

- Strategic Significance: First company to join Science's BCI Ecosystem program; enables Neurosoft to focus on core soft electrode innovations while leveraging Science's infrastructure

Awards and Recognition (2026)

- January 2026: Winner of 2026 Startup World Cup Las Vegas Regional Competition at CES; selected from approximately 500 applicants across 13+ countries

- Prize: Advancement to Grand Finale in San Francisco (November 2026) to compete for $1,000,000 investment

- January 2026: Won 1st Prize in AI Vertical at Global Deep Tech Battle (GDTB) at CES Las Vegas

Core Technology and Product Pipeline

SOFT ECoG™ Brain Interface

The flagship SOFT ECoG™ is a family of subdural electrodes for brain signal recording or stimulation:

- Design: Ultra-flexible, conformable, and stretchable soft brain interface

- Applications: Intra-operative use or sub-chronic implantation (up to 30 days)

- Clinical Use: Precise identification of epileptogenic brain tissue in drug-resistant epilepsy; brain surface mapping and monitoring during resection surgeries

- Manufacturing: Semiconductor industry-inspired processes enabling wide range of designs, reduced electrode size and pitch

- Differentiation: Enhanced flexibility and stretchability optimize interface with brain tissue compared to traditional rigid electrodes

MINDZ™ Minimally Invasive Neuro Device

- Design: Brain interface implantable on brain surface using minimally invasive deployment system

- Technology: Leverages soft mechanical properties allowing folding and unfolding in extreme form factors without device damage

- First Application: Localization of epileptic foci for patients with drug-resistant epilepsy

- Advantage: Inserted through burr hole instead of large craniotomy, reducing surgery time, recovery time, and infection risk

Synapsuit Upper-Limb Motor Restoration

- Goal: Assist people living with severe upper-limb motor disabilities

- Technology: Soft brain interface with AI algorithm to decode brain signals controlling lightweight soft wearable exosuit

- Function: Real-time support for arm and hand movements

- Collaboration: Ongoing project with Wyss Center for Bio and Neuroengineering, Korea Electronics Technology Institute, and Jang EUN FnC

Target Applications

Primary Indications:

- Tinnitus: Restorative treatment through neural stimulation

- Epilepsy: Drug-resistant epilepsy monitoring and treatment; identification of epileptogenic zones

- Other Neurological Disorders: Severe paralysis, Parkinson's disease, chronic pain

Long-term Vision:

- Full-cortical coverage neural data platform

- Foundation AI model of the human cortex

- Translation of noisy signals from everyday wearables into precise human intent

- Mass-market, non-invasive precise and reliable BCIs

Strategic Partnerships

- Science Corporation (2026): BCI Ecosystem partnership providing access to clinical-grade neural recording infrastructure

- Wyss Center for Bio and Neuroengineering: Collaboration support for technological and clinical advancements

- FONGIT: Geneva-based technology innovation foundation support

- UMC Utrecht: Clinical trial collaboration for epilepsy applications

- Korea Electronics Technology Institute & Jang EUN FnC: Synapsuit development partners

Competitive Landscape

Market Context:

- Global neurology devices market projected to exceed $25 billion by 2034

- BCI early total addressable market (TAM) estimated at $80 billion across 3 million US adults (Morgan Stanley)

- Potential to reach $320 billion with further advancements

Key Competitors: Neuralink (Elon Musk), Synchron, Paradromics, Blackrock Neurotech, InBrain Neuroelectronics

Differentiation:

- Soft Materials: Ultra-flexible, stretchable electrodes vs. traditional rigid electrodes

- Minimally Invasive: Burr hole implantation vs. large craniotomy

- Dual Purpose: Clinical treatment + high-fidelity neural data collection for AI model training

- Full-Cortical Coverage: Ambition to achieve comprehensive brain mapping vs. localized recording

Regulatory and Clinical Pathway

- Current Status: Clinical trials ongoing at UMC Utrecht (Netherlands)

- European Regulatory: Working toward European regulatory approval for epilepsy surgery centers

- Clinical Validation: 12-patient study funded by European Research Council (ERC)

Leadership Team

Executive Leadership

Chief Executive Officer & Co-founder: Nicolas Vachicouras, PhD

- EPFL background in neural engineering

- Led company through Series A funding and Science Corporation partnership

- Scientific adviser to Wyss Center for Bio and Neuroengineering

Co-founder: Ludovic Serex

- Led company pitch at CES 2026 Global Deep Tech Battle (AI Vertical 1st Prize)

Company Information

Corporate Details

Legal Name: Neurosoft Bioelectronics SA

Founded: 2020

Headquarters: Geneva, Switzerland

Origin: EPFL (École polytechnique fédérale de Lausanne) spin-off

Status: Private company (venture-backed)

Industry: Medical Devices - Neural Engineering / Brain-Computer Interfaces / Neurotechnology

Total Funding: CHF 2.75 million+ (Venture Kick, FONGIT, Innosuisse, Kickfund)

Contact Information

Website: www.neurosoft-bio.com

Email: contact@neurosoft-bio.com

Keywords: Neurosoft Bioelectronics, SOFT ECoG, MINDZ, Synapsuit, BCI, brain-computer interface, neural implant, soft electrode, Nicolas Vachicouras, Ludovic Serex, EPFL, Geneva, Science Corporation, Science Ecosystem, Startup World Cup, tinnitus, epilepsy, UMC Utrecht, Wyss Center, minimally invasive, 2020 founded